ClinicalTrials.gov
public full text
Public Domain
N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma
RATIONALE: CEP-701 may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of CEP-701 in treating young patients with recurrent or refractory high-risk neuroblastoma.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Antineoplaston Therapy in Treating Adults With Residual/Recurrent/Progressive Glioblastoma Multiforme#917733
- AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors#807066
- Einfluss der unterschiedlichen <i>Second-line</i>-Therapien bei rezidivierten Glioblastom Patienten - eine retrospektive, monozentrische Studie / Hannah Fischer ; Gutachter: Marion Rapp, Anna Gertrud Brunn#983193
- VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Therapy#802143
- First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies#1163163
Record · ID 1126676
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive